A Translational Study of a New Therapeutic Approach for Acute Myocardial Infarction: Nanoparticle-Mediated Delivery of Pitavastatin into Reperfused Myocardium Reduces Ischemia-Reperfusion Injury in a Preclinical Porcine Model

Kenzo Ichimura¹, Tetsuya Matoba¹, Kaku Nakano², Masaki Tokutome¹, Katsuya Honda¹, Jun-ichiro Koga², Kensuke Egashira²*

¹ Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, ² Department of Cardiovascular Research, Development, and Translational Medicine, Center for Cardiovascular Disruptive Innovation, Kyushu University, Fukuoka, Japan

Abstract

Background

There is an unmet need to develop an innovative cardioprotective modality for acute myocardial infarction, for which interventional reperfusion therapy is hampered by ischemia-reperfusion (IR) injury. We recently reported that bioabsorbable poly(lactic acid/glycolic acid) (PLGA) nanoparticle-mediated treatment with pitavastatin (pitavastatin-NP) exerts a cardioprotective effect in a rat IR injury model by activating the PI3K-Akt pathway and inhibiting inflammation. To obtain preclinical proof-of-concept evidence, in this study, we examined the effect of pitavastatin-NP on myocardial IR injury in conscious and anesthetized pig models.

Methods and Results

Eighty-four Bama mini-pigs were surgically implanted with a pneumatic cuff occluder at the left circumflex coronary artery (LCx) and telemetry transmitters to continuously monitor electrocardiogram as well as to monitor arterial blood pressure and heart rate. The LCx was occluded for 60 minutes, followed by 24 hours of reperfusion under conscious conditions. Intravenous administration of pitavastatin-NP containing ≥ 8 mg/body of pitavastatin 5 minutes before reperfusion significantly reduced infarct size; by contrast, pitavastatin alone (8 mg/kg) showed no therapeutic effects. Pitavastatin-NP produced anti-apoptotic effects on cultured cardiomyocytes in vitro. Cardiac magnetic resonance imaging performed 4 weeks after IR injury revealed that pitavastatin-NP reduced the extent of left ventricle remodeling. Importantly, pitavastatin-NP exerted no significant effects on blood pressure,
Pitavastatin-Nanoparticle for Myocardial Ischemia Reperfusion Injury

Introduction

Coronary heart disease is the leading cause of death worldwide, and acute myocardial infarction (AMI) is the most severe manifestation of this disease\[1\]. Myocardial infarct (MI) size is a major determinant of the clinical outcomes and prognosis in patients with AMI\[2\], and early reperfusion therapy is a standard strategy to reduce MI size. However, reperfusion induces ischemia-reperfusion (IR) injury, which reduces the therapeutic effects of reperfusion therapy \[3\]. Therefore, there is an unmet need to develop new cardioprotective modalities to reduce IR injury.

In previous studies, we exploited the cardioprotective effects of the 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors (statins)\[4\] to engineer bioabsorbable poly(lactic acid/glycolic acid) (PLGA) polymers loaded with pitavastatin (pitavastatin-NP)\[5–14\] and showed that intravenous treatment with pitavastatin-NP at the time of reperfusion exerts a cardioprotective effect in rats subjected to IR injury\[9\]. This cardioprotective effect was associated with activation of the PI3K-Akt pathway and reduced inflammation\[9\]. Although our results in a rat model showed the efficacy of pitavastatin-NP in IR injury reduction, an assessment of the efficacy and safety of pitavastatin-NP in a large animal model, particularly with regard to its safety in hemodynamics and coronary circulation, is necessary to translate our previous findings to clinical medicine.

Recently, porcine models have gained recognition as an effective preclinical large animal IR model to examine the effects of various drugs and interventions on IR injury and the resulting MI size\[15,16\]. However, there are some methodological problems associated with large animal IR models. First, most studies have been performed under general anesthesia, which may affect sympathetic nerve activity, hemodynamic status, cardiac function, and, subsequently, MI size. Moreover, while some anesthetics exert cardiotoxic side effects, which can exacerbate IR injury \[16,17\], others exert cardioprotective effects on IR injury\[18,19\]. Second, anesthetized porcine models of myocardial ischemia display high mortality rates due to fatal arrhythmia, such as ventricular fibrillation, within 24 hours of ischemia\[20–23\], which may introduce bias into results based on the exclusion of dead animals.

In the present study, to overcome these problems, we developed a novel conscious mini-pig myocardial IR injury model and performed a preclinical proof-of-concept study to test the hypothesis that pitavastatin-NP is a safe and effective therapeutic modality that can offer cardioprotection against IR injury. We used Bama mini-pigs because the metabolism of statins in this animal are similar to those in humans\[24\]. In addition, we performed exploratory analyses such as pharmacokinetics and the effects on no-reflow phenomenon in anesthetized pig model.
Materials and Methods
Preparation of PLGA Nanoparticles
PLGA with an average molecular weight of 20,000 Da and a copolymer ratio of lactide to glycolide of 75:25 (Wako Pure Chemical Industries, Osaka, Japan) was used as a matrix for the nanoparticles, and polyvinyl alcohol (PVA-403; Kuraray, Osaka, Japan) was used as a dispersing agent. PLGA nanoparticles incorporating the fluorescent marker fluorescein-isothiocyanate (FITC; Dojin Chemical, Tokyo, Japan) (FITC-NP) or pitavastatin (Kowa Pharmaceutical, Tokyo, Japan) (pitavastatin-NP) were prepared by the emulsion solvent diffusion method in purified water, as previously described[9,25]. The FITC-NP and pitavastatin-NP contained 4.2% (wt/vol) FITC and 12.0% (wt/vol) pitavastatin, respectively. A sample of the NP suspension in distilled water was used for particle size analysis. The average diameters of FITC-NP and pitavastatin-NP were 231 nm and 159 nm, respectively. Surface charge (zeta potential) was also analyzed using a Zetasizer Nano system (Sysmex, Hyogo, Japan) revealing an anionic nature [-16.7 mV (FITC-NP) and -4.1 mV (pitavastatin-NP)].

Care and Use of Animals
We utilized two types of animals in the present study; Bama mini-pigs and domestic pigs. The experiment using Bama mini-pig was conducted in JOINN laboratories Inc. (http://www.joinnlaboratories.com/home/index2.html), in Suzhou, China. JOINN was accredited by AAA-LAC in 2011 by China FDA. This experiment was reviewed and approved by the local ethics committee in JOINN laboratories. The experiments using domestic pigs were conducted in Kyushu University, reviewed and approved by the Committee of Ethics of Animal Experiments at Kyushu University Graduate School of Medical Science. Both experiments were conducted according to the guidelines of the Guide for the Care and Use of Laboratory Animals from the National Institutes of Health (NIH).

Animals were kept in a separate cage in a room which temperature was kept between 18 to 26°C, humidity between 40 to 70% and the lights were kept on between 6:30 am to 6:30 pm. Normal chow diet were given twice daily and water was supplied ad libitum. The physical condition of animals was checked twice daily, and 6 times daily after surgical preparation. Veterinary physicians with expertise to perform the pig experiments were asked to attend and observe the course of experiment. At the end of each experiments, animals were euthanized by an overdose of pentobarbital.

Conscious Mini-Pig Model of IR injury
Eighty-four Bama mini-pigs[24] (aged 4–6 months, weight 10–15 kg) were used in this study. The animals were anesthetized with ketamine hydrochloride (20 mg/kg i.m.; Daiichi-Sankyo Propharma, Tokyo, Japan) and xylazine (3.5 mg/kg, Sigma-Aldrich, MO) and were maintained under anesthesia with isoflurane (1% to 2.5%, Abbvie, IL) using a ventilator after intubation. Under aseptic conditions, a left thoracotomy was performed, and a pneumatic cuff occluder (VO-2, Docxs Biomedical Products and Accessories, CA) was placed at the proximal portion of the left circumflex coronary artery (LCx). A telemetry transmitter system (TL11M2-D70-PCT, Data Sciences International Inc., MN) was implanted in the subcutaneous space of the abdomen, and the tip of the manometer was placed in the abdominal aorta through the left femoral artery. After the chest was closed, the animals were allowed to recover from surgery. On the day after surgery, the LCx was occluded for 60 minutes by inflating the cuff, and then the tissue was reperfused by deflating the cuff. Transmural ischemia was confirmed by observing ST segment elevation by electrocardiography. Five minutes prior to
reperfusion, the pigs were divided into four groups treated with intravenous injection of one of the following drugs: 1) saline (10 mL/body), 2) FITC-NP (PLGA containing 10 mg of FITC in saline; 10 mL/body), 3) pitavastatin alone (8 mg in saline; 10 mL/body), or 4) pitavastatin-NP (PLGA containing 4, 8, 16, or 32 mg of pitavastatin in saline; 10 mL/body). Before and during the IR procedure, an electrocardiogram at the left precordial lead, arterial blood pressure, heart rate and body temperature were continuously monitored using a telemetry system. Blood samples were collected at baseline (1 hour prior to ischemia) and 24 hours after reperfusion.

To measure MI size, the animals were euthanized 24 hours after reperfusion with an overdose of pentobarbital, and the heart was excised (S1A Fig). The LCx was re-occluded, and the MI size was measured using 1.0% Evans blue (Sigma-Aldrich) and 1.0% triphenyltetrazolium chloride staining (TTC, Sigma-Aldrich), as previously described[23]. For western blot and immunohistochemical analyses, pigs treated with FITC-NP (PLGA containing 10 mg of FITC in saline; 10 mL/body) or pitavastatin-NP (PLGA containing 16 mg of pitavastatin in saline; 10 mL/body) were euthanized after 2 or 24 hours of reperfusion, and the tissues were harvested from the non-ischemic and ischemic areas (S1B and S1C Fig). Seven pigs each from the saline (10 mL/body) or pitavastatin-NP (PLGA containing 16 mg of pitavastatin in saline; 10 mL/body)-treated groups were monitored until 4 weeks after reperfusion, and then cardiac MRI was performed to assess cardiac function and left ventricular remodeling (S1D Fig).

Assessment of Cardiac Function and remodeling by Magnetic Resonance Imaging (MRI). Cardiac function and remodeling were assessed using a cardiac 3.0 Tesla MRI (MAGNETOM, Siemens Medical Solutions, Erlangen, Germany) 4 weeks after IR injury in the saline- or pitavastatin-NP-treated (16 mg/body) animals (S1D Fig). The animals were injected with a bolus (equal volumes at a concentration of 0.075 mmol/kg) of a 1 M gadolinium-based contrast agent (gadobutrol/Gadovist, Berlin-Wedding, Schering, Germany) at 4 mL/s, followed by a 20-mL saline flush using a power injector via another venous line. The left ventricular ejection fraction (LVEF) was manually calculated by tracing the endocardial borders at end systole and end diastole for each short axis slice. The LV mass was calculated according to the equation LV mass = Σ(slice thickness×muscle size×myocardial density), as previously described[26].

Western Blot Analysis. Tissues were harvested from the non-ischemic and ischemic areas and were snap frozen in liquid nitrogen. The samples were homogenized using a cryopress (CP-100W, Microtec, Chiba, Japan) in lysis buffer containing 10 mmol/L Tris-HCl, pH 7.4, 5 mmol/L EDTA, 50 mmol/L NaCl, 30 mmol/L sodium phosphate, 50 mmol/L NaF, 1% Triton X-100, a protease inhibitor cocktail (Thermo Fisher Scientific, MA) and a phosphatase inhibitor cocktail (Thermo Fisher Scientific, MA). Tissue lysates (10 μg) were separated on 7.5% polyacrylamide gels and blotted onto polyvinylidene fluoride membranes (Merck Millipore, MA). Protein expression was analyzed using antibodies against Akt (Cell Signaling Technology, MA), p-Akt (Cell Signaling Technology, MA) or GAPDH (Santa Cruz Biotechnology, CA). Immune complexes were visualized with horseradish peroxidase-conjugated secondary antibodies. The bound antibodies were detected by chemiluminescence with the ECL Prime western blotting detection system (GE Healthcare, CT) and were quantified by densitometry.

Immunohistochemistry. Tissues from the non-ischemic and ischemic areas were processed by routine paraffin embedding. The degree of oxidative stress was assessed by immunohistochemical staining of 5-μm sections with anti-8-hydroxy-2’-deoxyguanosine (8-OHdG) (dilution 1:40, Nikken Seil, Shizuoka, Japan) and anti-4-hydroxy-2-nonenal (4-HNE) (dilution 1:20, Nikken Seil). Apoptotic nuclei were detected by terminal deoxynucleotidyl-transferase mediated dUTP nick-end labeling (TUNEL) staining using the In Situ Apoptosis Detection Kit (Takara Bio, Shiga, Japan) according to the instructions recommended by the manufacturer.
Anesthetized Domestic Pig Model of IR Injury

Domestic male pigs (Kyudo, Tosu, Japan; aged 4–6 months, weight 25–35 kg) were anesthetized with ketamine hydrochloride (15 mg/kg, i.m.) and xylazine (3.5 mg/kg) and were maintained under anesthesia with isoflurane (5.0%) administered through a facemask. The pigs were then intubated and mechanically ventilated with ambient air and isoflurane (1.0–2.0%). A mid-sternal thoracotomy was performed, and the LCx was occluded for 1 hour, followed by reperfusion. Seven pigs were treated with saline, FITC (0.33 mg/kg in saline; 10 mL/body), or FITC-NP (PLGA containing 0.33 mg/kg FITC in saline; 10 mL/body) 5 minutes before reperfusion, and 2 hours after reperfusion, the pigs were euthanized, and the hearts were excised. The LCx was re-occluded, and 1.0% Evans blue was injected into both coronary arteries. The left ventricles were sectioned into 10-mm-thick cross-sectional myocardial slices and were photographed by fluorescence stereomicroscopy (SteREO Lumar V12, Zeiss, Oberkochen, Germany). Tissues from the non-ischemic or ischemic areas were evaluated by fluorescence microscopy (BX53, Olympus, Tokyo, Japan) (S2A Fig).

The other 10 pigs were intravenously injected with pitavastatin (16 mg/body in saline; 10 mL/body) or pitavastatin-NP (PLGA containing 16 mg of pitavastatin in saline; 10 mL/body) 5 minutes prior to reperfusion. Serial blood sampling and biopsy of ischemic and non-ischemic myocardium was performed at 5, 15, 30 or 60 minutes after reperfusion to measure the plasma and tissue concentrations of pitavastatin (S2B Fig). Biopsy specimens from the heart were harvested by using a 1.5 mm biopsy punch (BP-15F, Kai Industries Co., Ltd, Tokyo, Japan).

Measurement of Pitavastatin Concentrations in Plasma and Myocardial Tissue. The pitavastatin concentrations in the plasma and heart were measured by liquid chromatography coupled to tandem mass spectrometry (LC/MS/MS), as previously described[9]. Briefly, the high-performance liquid chromatography (HPLC) analysis was performed using an Agilent 1100 series system (Agilent Technologies, Inc., CA). The column temperature was maintained at 40°C. The flow rate was 0.3 mL/min. Pre-prepared plasma or tissue homogenate sample solutions were injected from the autosampler into the HPLC system. The turbo ion spray interface was operated in the positive ion mode at 4,800 V and 550°C. The analytical data were processed using Analyst software (version 1.4m, Applied Biosystems, CA).

Evaluation of the No-reflow Phenomenon. Another group of domestic male pigs that had been treated with saline (10 mL/body) or pitavastatin-NP (PLGA containing 16 mg of pitavastatin in saline; 10 mL/body) were reperfused for 2 hours (S2C Fig), and 4% thioflavin S (Sigma-Aldrich) was injected into the left coronary artery via a 7-Fr catheter[27]. Then, the pigs were euthanized, and the hearts were excised. The LCx was re-occluded, and 1% Evans blue was injected into both coronary arteries. The left ventricles were sectioned into 10-mm-thick cross-sectional myocardial slices and were photographed using a digital camera (EOS Kiss X1Ia, Canon, Tokyo, Japan) and an Image Quant LAS 4010 (GE Healthcare, CT) using 365 nm UV epi-illumination and an L41 UV filter.

Preparation of Cultured Cardiomyocytes, Confocal Imaging and Flow Cytometric Analysis

A primary culture of neonatal rat ventricular myocytes was prepared from the ventricles of neonatal Sprague-Dawley rats (Kyudo), as previously described[28]. Briefly, neonatal rats were euthanized under anesthesia with isoflurane, after which the hearts were rapidly excised and digested with 0.05% trypsin (Thermo Fisher Scientific) and collagenase type 2 (Worthington, NJ). After digestion, the cells were suspended in Dulbecco’s Modified Eagle Medium (DMEM, Thermo Fisher Scientific) containing 10% fetal bovine serum (FBS, Thermo Fisher Scientific) and 1% penicillin/streptomycin (Thermo Fisher Scientific) and were plated twice in 100-mm
culture dishes (Cellstar, Greiner Bio-One, NY) for 70 minutes each to reduce the number of non-myocytes. The non-adherent cells were then plated in 35-mm culture dishes (Primaria, BD Biosciences, CA) at a density of 1.0×10⁶ cells/3 mL DMEM. Myocytes were maintained at 37°C in humidified air with 5% CO₂ for 36 hours after plating on culture dishes.

Cultured myocytes were incubated in DMEM without glucose (Sigma-Aldrich) in a hypoxic chamber (1% O₂) for 12 hours. The following experimental protocols were performed after the hypoxic period.

Experimental protocol 1: The culture medium was exchanged with normal DMEM containing the following drugs: 1) pitavastatin alone (0.1, 1.0, or 10 μmol/L), 2) pitavastatin-NP (0.1, 1.0, or 10 μmol/L), and 3) pitavastatin-NP (0.1, 1.0, or 10 μmol/L) with mevalonic acid (100 μmol/L, Sigma-Aldrich). The myocytes were further cultured in humidified air with 5% CO₂ for 12 hours. After the incubation period, the myocytes were washed with cold Dulbecco’s phosphate-buffered saline (DPBS, Thermo Fisher Scientific) twice, dissociated from the dish using 1 mL of accutase (Innovative Cell Technologies, CA), and cell death was assessed by flow cytometry (Galios, Beckman Coulter, CA) using the FITC annexin-V apoptosis detection kit (BD Biosciences) according to the instructions recommended by the manufacturer, as previously described[29].

Experimental protocol 2: The culture medium was exchanged with normal DMEM containing FITC (10 μmol/L) or FITC-NP (10 μmol/L). The myocytes were further cultured in humidified air with 5% CO₂ for 12 hours. After the incubation period, the myocytes were washed with cold DPBS twice, fixed with methanol at -20°C for 20 min, and mounted with medium containing DAPI (Vectashield, Vector Laboratories, CA). Images of the cardiomyocytes were captured by confocal microscopy (FV1000, OLYMPUS, Tokyo, Japan).

Statistical Analysis

The data are expressed as either means ± SD or means ± SEM. The statistical analysis of differences between two groups was assessed using an unpaired t-test, and differences between three or more groups were assessed using ANOVA and multiple comparison tests featured in Prism Software version 6.0 (Graph Pad Software, CA). P-values <0.05 were considered statistically significant.

Results

Cardioprotective Effects of Pitavastatin-NP in Conscious Mini-Pigs

No animals died during the surgical preparations before the IR experiments. One animal died during the induction of ischemia (S3A Fig).

We observed no difference in mortality during the 24 hours of reperfusion among the saline- (n = 7), FITC-NP- (n = 4), pitavastatin- (n = 3), and pitavastatin-NP-treated (n = 33) groups (S3A Fig). Compared with the control group (saline and FITC-NP groups), intravenous treatment with pitavastatin-NP containing 8, 16 or 32 mg/kg pitavastatin at the time of reperfusion significantly reduced the MI size (Fig 1A and 1B). In contrast, treatment with pitavastatin-NP containing 4 mg/kg of pitavastatin did not reduce the MI size (Fig 1B). The percentage of area at risk in the left ventricle was comparable between all study groups (Fig 1C). There was no significant difference in the MI size between the saline-treated and FITC-NP-treated animals (S4A and S4B Fig). Treatment with pitavastatin alone at a dose of 8 mg/body did not reduce the MI size compared with the same dose of pitavastatin-NP (S4C and S4D Fig).

Cardiac MRI performed 4 weeks after IR injury showed that treatment with pitavastatin-NP (16 mg/body of pitavastatin) tended towards an improvement in the left ventricular ejection fraction, although these results did not reach statistical significance: 50.1 ± 5.0% in the
pitavastatin-NP group and 41.8 ± 9.3% in the saline group (P = 0.064, n = 6–7 each) (Table 1, Fig 2A). The left ventricular end systolic volume was significantly decreased in the pitavastatin-NP-treated group, 12.3 ± 2.3 mL in the pitavastatin-NP group and 17.1 ± 5.0 mL in the saline group (P < 0.05, n = 6–7 each), which suggests that the remodeling of the left ventricle was improved by pitavastatin-NP treatment (Fig 2A and 2B).

We observed no significant differences in blood pressure and heart rate among the saline-, FITC-NP-, pitavastatin- and pitavastatin-NP-treated groups (Table 2). Moreover, we observed no significant difference in the incidence of ventricular arrhythmias (premature ventricular contraction and non-fatal ventricular tachycardia) between the treatment groups (Table 3). We observed no significant difference between all treated groups with regard to liver function, renal function and lipid metabolism (Table 4).

Because we previously reported that Akt phosphorylation in the IR-injured myocardium was critical for cardioprotection in a rat model[9], we examined the phosphorylation of Akt in
the pig model by western blotting myocardial tissue 2 hours after reperfusion. Consistent with our previous results, pitavastatin-NP treatment induced Akt phosphorylation at Thr308 in the ischemic area (Fig 3A). Immunohistochemistry analysis of 8-OHdG and 4-HNE revealed that oxidative stress in the cardiomyocytes in the ischemic area was significantly reduced by pitavastatin-NP treatment 24 hours after reperfusion (Fig 3B). Consistently, TUNEL staining showed that apoptotic cells were significantly reduced in the ischemic area in the pitavastatin-NP-treated animals 24 hours after reperfusion (Fig 3C). These data are consistent with our previous study of pitavastatin-NP in a rat IR model[9].

Effects of Pitavastatin-NP on Pharmacokinetics and the No-Reflow Phenomenon in Anesthetized Domestic Pigs

FITC-NP was injected 5 minutes prior to reperfusion, and the distribution of PLGA-NP in the heart was evaluated 2 hours later (S2A Fig). The FITC signal was exclusively detected in the ischemic area, whereas a faint FITC signal was observed in the non-ischemic area of the myocardium of animals treated with saline or FITC alone (Fig 4A). Histopathological examination of the heart sections detected FITC signals in the ischemic myocardium, which was more significant than in the non-ischemic myocardium (Fig 4B).

To evaluate the pharmacokinetics of intravenously injected pitavastatin-NP, serial blood sampling and biopsy of ischemic and non-ischemic myocardium was performed 5, 15, 30 and 60 minutes after injection of pitavastatin-NP or pitavastatin (S2B Fig). As we previously reported in a rat IR model[9], the plasma pitavastatin concentration immediately (5 minutes) after intravenous administration was significantly higher in the pitavastatin-NP group than in the pitavastatin-alone group, and the time-dose relationship was different (Fig 4C, Table 5).

The area of no-reflow was quantified by thioflavin-S staining 2 hours after reperfusion (S2C Fig). Treatment with pitavastatin-NP containing 16 mg/body pitavastatin did not affect the areas of no-reflow or areas at risk compared with the saline-treated group (Fig 5).

Effects of Pitavastatin-NP on Cardiomyocyte Cell Death

Cell death was induced by hypoxia in cultured cardiomyocytes, followed by reoxygenation. The cells were treated with vehicle, pitavastatin (0.1, 1.0 or 10 μmol/L) or pitavastatin-NP (0.1, 1.0 or 10 μmol/L of pitavastatin) at the time of reoxygenation. Cell death was characterized as

| Table 1. Cardiac MRI studies. |
|-------------------------------|
|                              | Saline             | Pitavastatin-NP 16 mg/body |
| LVEDV (mL)                   | 30.0 ± 4.2         | 25.1 ± 2.5               |
| LVESV (mL)                   | 17.1 ± 2.1         | 12.3 ± 0.9 *             |
| LVEF (%)                     | 41.8 ± 3.8         | 50.1 ± 1.9               |
| LVEDV index (mL/kg)          | 1.66 ± 0.18        | 1.66 ± 0.11              |
| LVESV index (mL/kg)          | 0.96 ± 0.11        | 0.82 ± 0.05              |
| LV mass (g)                  | 43.2 ± 3.7         | 36.5 ± 3.1               |
| LV mass index (g/kg)         | 2.43 ± 0.20        | 2.42 ± 0.12              |

The data are expressed as the mean ± SD (n = 6–7 each).
LVEDV: left ventricular end diastolic volume, LVESV: left ventricular end systolic volume, LVEF: left ventricular ejection fraction, LV: left ventricular

* P<0.05 versus control using t-test.

doi:10.1371/journal.pone.0162425.t001
apoptosis (annexin V–FITC staining) or necrosis (PI staining) by flow cytometry. Pitavastatin-NP at doses of 1.0 μmol/L and 10 μmol/L significantly reduced the rate of apoptosis of cardiomyocytes undergoing hypoxia/reoxygenation, but pitavastatin alone at the same dose or pitavastatin-NP at a dose of 0.1 μmol/L did not produce the same effect (Fig 6A). This anti-

Fig 2. Assessment of Left Ventricular Ejection Fraction (LVEF) and Left Ventricular Remodeling by MRI in Mini-Pigs. (A) LVEF, left ventricular end diastolic volume (LVEDV) and left ventricular end systolic volume (LVESV) 4 weeks after reperfusion in the saline- or pitavastatin-NP (16 mg/body pitavastatin)-treated groups were measured by cardiac MRI. The data are expressed as means ± SEM (n = 6–7 each) and were compared using an unpaired t-test. (B) Representative photographs of heart cross-sections 4 weeks after reperfusion in the saline- and pitavastatin-NP-treated groups. Scale bar: 1 cm.

doi:10.1371/journal.pone.0162425.g002
Table 2. Blood pressure and heart rate during ischemia-reperfusion in conscious mini-pig model.

| Groups          | Dose (/body) | Baseline | Ischemia | Reperfusion |
|-----------------|--------------|----------|----------|-------------|
|                 |              |          |          | 0 min | 1 hr | 3 hr | 5 hr | 8 hr | 24 hr |
| Saline          | -            | 116 ± 9  | 105 ± 8  |       |       |       |       |       |       |
| Pitavastatin    | 8 mg         | 115 ± 9  | 113 ± 9  | 119 ± 9 | 114 ± 20| 123 ± 30| 122 ± 23| 123 ± 30| 128 ± 36|
| FITC-NP         | 10 mg        | 107 ± 10 | 100 ± 3  | 103 ± 9 | 90 ± 20 | 85 ± 17*| 91 ± 17 | 96 ± 15 | 96 ± 11 |
|                 | 4 mg         | 104 ± 16 | 113 ± 9  | 106 ± 7 | 112 ± 9 | 108 ± 12| 110 ± 10| 113 ± 12| 120 ± 5 |
| Pitavastatin-NP | 8 mg         | 105 ± 12 | 106 ± 15 | 108 ± 13| 109 ± 14| 106 ± 16| 108 ± 7 | 111 ± 16| 118 ± 15|
|                 | 16 mg        | 113 ± 28 | 107 ± 5  | 102 ± 7 | 97 ± 0  | 95 ± 7  | 99 ± 2  | 103 ± 10| 108 ± 16|
|                  |              | 70 ± 7   | 72 ± 10  | 66 ± 4  | 64 ± 1  | 64 ± 7  | 69 ± 7  | 64 ± 11 | 64 ± 7  |
| Pitavastatin-NP | 8 mg         | 115 ± 9  | 113 ± 9  | 119 ± 9 | 114 ± 20| 123 ± 30| 122 ± 23| 123 ± 30| 128 ± 36|
| FITC-NP         | 10 mg        | 107 ± 10 | 100 ± 3  | 103 ± 9 | 90 ± 20 | 85 ± 17*| 91 ± 17 | 96 ± 15 | 96 ± 11 |
|                 | 4 mg         | 104 ± 16 | 113 ± 9  | 106 ± 7 | 112 ± 9 | 108 ± 12| 110 ± 10| 113 ± 12| 120 ± 5 |
| Pitavastatin-NP | 8 mg         | 105 ± 12 | 106 ± 15 | 108 ± 13| 109 ± 14| 106 ± 16| 108 ± 7 | 111 ± 16| 118 ± 15|
|                 | 16 mg        | 113 ± 28 | 107 ± 5  | 102 ± 7 | 97 ± 0  | 95 ± 7  | 99 ± 2  | 103 ± 10| 108 ± 16|

The data are expressed as the mean ± Standard Deviation (n = 3–6 each).

* P<0.05 versus pitavastatin (3 hr) using two-way ANOVA followed by Bonferroni’s multiple comparison test.

doi:10.1371/journal.pone.0162425.t002

apoptotic effect was inhibited by co-treatment with mevalonic acid (100 μmol/L). Although there was a trend that pitavastatin-NP reduced the rate of necrosis compared with pitavastatin alone at each dose, this difference did not reach statistical significance (Fig 6A).

To determine the intracellular localization of the nanoparticles, cardiomyocytes were treated with FITC or FITC-NP. Cardiomyocytes treated with FITC-NP had a significantly stronger intracellular FITC fluorescence intensity compared with those treated with the same amount of FITC alone (Fig 6B and 6C).
Discussion

In the present study, we performed a preclinical proof-of-concept study in a conscious mini-pig myocardial IR model and found that treatment with pitavastatin-NP protects the heart from IR injury without apparent adverse side effects. In addition, pitavastatin-NP tended to attenuate post-infarction left ventricular remodeling and improved cardiac function.

The mini-pig myocardial IR injury model presented here showed stable hemodynamics, without abnormal changes in blood pressure and heart rate, as well as a low incidence of fatal arrhythmia and low mortality during the experimental period. Our data suggest that the efficacy and safety of pitavastatin-NP in our conscious mini-pig model are highly reliable, and this new model is a more appropriate and feasible preclinical model for IR injury compared with anesthetized large animal models. In the present study, we found that pitavastatin-NP reduced the MI size at doses of 8, 16 and 32 mg/body, suggesting that an appropriate dose of pitavastatin-NP in human patients would range from 8 to 16 mg/body. In addition, cardiac MRI performed 4 weeks after IR injury demonstrated that treatment with pitavastatin-NP decreased

Table 3. Numbers of arrhythmias during ischemia-reperfusion in conscious mini-pig model.

| Groups       | Dose (/body) | Ischemia 0 - 1 hr | Reperfusion 0 - 1 hr | 1 - 4 hr | 4 - 24 hr |
|--------------|--------------|-------------------|----------------------|----------|----------|
|              | VT*          | PVC**             | VT*                  | PVC**    | VT*      | PVC**    |
| Saline       | -            | 0.8 ± 0.6         | 39 ± 26              | 122 ± 62 | 121 ± 54 | 21 ± 8   | 45 ± 19 | 0 ± 0    | 6 ± 3    |
| Pitavastatin | 8 mg         | 1.3 ± 1.2         | 16 ± 14              | 81 ± 50  | 105 ± 65 | 33 ± 23  | 48 ± 32 | 0 ± 0    | 11 ± 8   |
| FITC-NPs     | 10 mg        | 7 ± 7             | 46 ± 38              | 104 ± 55 | 96 ± 11  | 24 ± 14  | 46 ± 22 | 0 ± 0    | 10 ± 4   |
| Pitavastatin-NPs | 4 mg       | 10 ± 6            | 145 ± 106            | 42 ± 24  | 139 ± 74 | 8 ± 5    | 37 ± 21 | 0 ± 0    | 20 ± 15  |
|              | 8 mg         | 0 ± 0             | 4.9 ± 2.3            | 137 ± 88 | 141 ± 43 | 20 ± 11  | 31 ± 6  | 0 ± 0    | 12 ± 5   |
|              | 16 mg        | 1.2 ± 1.2         | 23 ± 20              | 102 ± 46 | 67 ± 24  | 10 ± 6   | 29 ± 12 | 0 ± 0    | 6 ± 4    |

The data are expressed as the mean ± SD (n = 3–6 each).
* VT: >3 consecutive ventricular beats.
** PVC: premature ventricular contraction

doi:10.1371/journal.pone.0162425.t003

Table 4. Liver function, renal function and lipid profiles.

| Time (after Reperfusion) | Saline | Pitavastatin 8 mg/body | Pitavastatin-NP (/body) |
|--------------------------|--------|------------------------|-------------------------|
|                          | AST (IU/L) | 4 mg | 8 mg | 16 mg | 32 mg | AST (IU/L) | 4 mg | 8 mg | 16 mg | 32 mg |
| - 2hr                    | 72 ± 2   | 57 ± 11                | 97 ± 42                 | 99 ± 18              | 105 ± 13               | 72 ± 10               |
| 24 hr                    | 56 ± 2   | 32 ± 2                 | 41 ± 10                 | 72 ± 14              | 79 ± 17                | 51 ± 4                |
| ALT (IU/L)               | 67 ± 4   | 62 ± 1                 | 60 ± 11                 | 79 ± 9               | 53 ± 5                 | 54 ± 4                |
| - 2hr                    | 76 ± 5   | 53 ± 6                 | 57 ± 8                  | 90 ± 14              | 60 ± 5                 | 60 ± 2                |
| 24 hr                    | 10 ± 1   | 16 ± 1                 | 14 ± 3                  | 12 ± 1               | 15 ± 2                 | 10 ± 1                |
| BUN (mg/dL)              | 9 ± 1    | 7 ± 0                  | 8 ± 2                   | 9 ± 1                | 11 ± 1                 | 7 ± 1                 |
| - 2hr                    | 0.6 ± 0.0| 0.5 ± 0.0              | 1.0 ± 0.0               | 0.5 ± 0.1            | 0.6 ± 0.0              | 1.0 ± 0.0             |
| 24 hr                    | 0.5 ± 0.0| 0.5 ± 0.1              | 0.5 ± 0.0               | 0.5 ± 0.0            | 0.5 ± 0.0              | 0.4 ± 0.0             |
| Creatinin (mg/dL)        | - 2hr    | 0.5 ± 0.0              | 0.6 ± 0.0               | 0.5 ± 0.1            | 0.6 ± 0.0              | 0.4 ± 0.0             |
|                          | 24 hr    | 0.5 ± 0.0              | 0.5 ± 0.1               | 0.5 ± 0.0            | 0.5 ± 0.0              | 0.4 ± 0.0             |
| Total cholesterol (mg/dL)| - 2hr    | 54 ± 5                 | 50 ± 3                  | 43 ± 6               | 45 ± 10               | 59 ± 4                |
|                          | 24 hr    | 75 ± 4                 | 72 ± 5                  | 70 ± 6               | 76 ± 5                | 74 ± 8                |
| Triglyceride (mg/dL)     | - 2hr    | 15 ± 3                 | 20 ± 3                  | 11 ± 3               | 10 ± 1                | 16 ± 4                |
|                          | 24 hr    | 36 ± 16                | 19 ± 1                  | 17 ± 1               | 19 ± 2                | 28 ± 8                |

The data are expressed as the mean ± SEM (n = 3–6 each).

doi:10.1371/journal.pone.0162425.t004
Fig 3. The Effect of Pitavastatin-NP on Akt Phosphorylation, Oxidative Stress and Apoptosis in Mini-Pigs. (A) Tissues from the ischemic and non-ischemic areas were analyzed by immunoblotting for phosphorylated Akt in the control and pitavastatin-NP (16 mg/body of pitavastatin) groups. The bar graph indicates the ratio of phosphorylated Akt to Akt. The data are expressed as means ± SD (n = 4–5 each) and were compared using an unpaired t-test. (B) Immunostaining with 8-OHdG and 4-HNE in the control and pitavastatin-NP (16 mg/body of pitavastatin) groups. The bar graph indicates the percentage of 8-OHdG-positive nuclei and 4-HNE-positive areas in 5 randomly selected fields. The data are expressed as means ± SD (n = 4–5 each) and were compared using an unpaired t-test. Scale bar: 100 μm. (C) TUNEL staining of the ischemic areas in the control and pitavastatin-NP (16 mg/body of pitavastatin) groups. Nuclei are counter stained with propidium iodide (PI). The bar graph indicates the percentage of TUNEL-positive cells in 5 randomly selected fields. The data are expressed as means ± SD (n = 4–5 each) and were compared using an unpaired t-test. Scale bar: 200 μm. NC: negative control.

doi:10.1371/journal.pone.0162425.g003
Fig 4. Selective Delivery of PLGA-NP to the Ischemic Myocardium and Pharmacokinetics of Pitavastatin-NP in Anesthetized Domestic Pigs. (A) Representative light (upper) and fluorescence (lower) images of heart cross-sections 2 hours after an intravenous injection of saline, FITC alone or FITC-NP. The Evans blue-stained areas in the upper row indicate the non-ischemic areas. FITC signals were exclusively detected in the ischemic area in the FITC-NP-treated group, whereas no FITC signal was observed in the saline- and FITC-treated groups. Scale bar: 1 cm.

(B) Tissue sections from the ischemic and non-ischemic myocardium (yellow rectangle in (A)). FITC signals were almost exclusively detected in the ischemic myocardium. Scale bar: 50 μm. The bar graph shows the quantitation of the FITC signals of 5 randomly selected high power fields from each area. The data are expressed as

Fig 4. Selective Delivery of PLGA-NP to the Ischemic Myocardium and Pharmacokinetics of Pitavastatin-NP in Anesthetized Domestic Pigs. (A) Representative light (upper) and fluorescence (lower) images of heart cross-sections 2 hours after an intravenous injection of saline, FITC alone or FITC-NP. The Evans blue-stained areas in the upper row indicate the non-ischemic areas. FITC signals were exclusively detected in the ischemic area in the FITC-NP-treated group, whereas no FITC signal was observed in the saline- and FITC-treated groups. Scale bar: 1 cm. (B) Tissue sections from the ischemic and non-ischemic myocardium (yellow rectangle in (A)). FITC signals were almost exclusively detected in the ischemic myocardium. Scale bar: 50 μm. The bar graph shows the quantitation of the FITC signals of 5 randomly selected high power fields from each area. The data are expressed as
the left ventricular end systolic volume and increased left ventricular ejection fraction compared with those on treatment with saline. However, the effects of pitavastatin-NP on left ventricular end diastolic volume did not achieve statistical significance. It is known that significant post-MI left ventricular remodeling (left ventricular dilatation associated with increased end diastolic volume) develops in animals and humans when more than 30% of the left ventricle fell into MI\[^{30,31}\]. The observed MI size in the none-treated control group was small (19 ± 7% of LV), which might lead to inadequate left ventricular remodeling. Therefore, further studies are needed to examine the effects of pitavastatin-NP on left ventricular remodeling and function during the chronic phases of IR injury.

Our present pharmacokinetic data in an anesthetized porcine model, showing higher plasma concentration of pitavastatin immediately after intravenous administration in the pitavastatin-NP group than in the pitavastatin-alone group, are comparable to our previous reports in a rat IR model\[^9\]. These data are also supported by prior reports demonstrating that PLGA nanoparticles prolong the in vivo circulation time of the nanoparticulated drug from minutes to several hours after intravenous administration \[^9,10,32\]. However, the observed tissue concentrations of pitavastatin between the ischemic and non-ischemic myocardium does not account for the superior therapeutic effect of pitavastatin-NP. Although the therapeutic target of statins is known to be an intracellular 3-hydroxy-3-methylglutaryl coenzyme-A reductase, it is impossible to measure intracellular concentration of pitavastatin or its metabolite in cardiomyocytes or inflammatory cells \textit{in vivo} by state-of-art methods. Therefore, further studies are needed to examine whether intracellular concentrations of pitavastatin are greater in cardiomyocytes and inflammatory cells in the ischemic myocardium than in those in the non-ischemic myocardium. In addition, thioflavin-S staining suggested that pitavastatin-NP showed no effect on the no-reflow phenomenon.

![Image](36x741 to 143x765)

**Table 5. Plasma and tissue concentration of pitavastatin after intravenous administration of pitavastatin-NP or pitavastatin at the time of reperfusion.**

| Groups            | Time after intravenous administration | T\(_{1/2}\) (min) | C\(_{\text{max}}\) | AUC          |
|-------------------|---------------------------------------|-------------------|-------------------|--------------|
|                   | 5 min 15 min 30 min 60 min             |                   |                   |              |
| Non-ischemic Area | 672 ± 114 478 ± 139 249 ±66 155 ± 84 | 95.5 ± 163       | 683 ± 94         | 315 ± 62     |
| Ischemic Area     | 559 ± 182 415 ± 36 381 ± 75 305 ± 29 | 116 ± 46.6       | 563 ± 176        | 375 ± 32     |
| Plasma            | 1335 ± 221* 686 ± 169 435 ± 113 193 ± 32 | 25.6 ± 4.02      | 941 ± 341        | 521 ± 106*   |

| Groups            | Time after intravenous administration | T\(_{1/2}\) (min) | C\(_{\text{max}}\) | AUC          |
|-------------------|---------------------------------------|-------------------|-------------------|--------------|
|                   | 5 min 15 min 30 min 60 min             |                   |                   |              |
| Non-ischemic Area | 415 ± 87 250± 84 145 ± 51 190 ± 144 | 98.5 ± 117       | 415 ± 86         | 205 ± 73     |
| Ischemic Area     | 434 ± 203 431 ± 76 325 ± 166 264 ± 145 | 76.1 ± 45.5      | 558 ± 90         | 331 ± 91     |
| Plasma            | 941 ± 342 412 ± 127 258 ± 75 119 ± 55 | 25.5 ± 5.05      | 1335 ± 221      | 329 ± 93     |

Data are expressed as mean ± SD (ng/g tissue for myocardial tissue and ng/mL for plasma, ng.hr/g tissue for AUC of myocardial tissue, ng.hr/mL for AUC of plasma, n = 5 each).

* P<0.01 versus pitavastatin group by 2way ANOVA followed by Sidak’s multiple comparisons test.

![Image](36x741 to 143x765)
We have previously reported that PLGA nanoparticles are selectively delivered to cardiomyocytes and inflammatory cells (mainly monocytes) in IR-injured myocardium after an intravenous injection at the time of reperfusion\cite{8,9}. Moreover, our results suggested that PLGA nanoparticles are a clinically feasible drug delivery system for IR injury. We also reported that the cardioprotective effect of pitavastatin-NP on IR injury was mediated by inhibiting monocyte-mediated inflammation as well as the resulting cardiomyocyte apoptosis occurring during the late phase of reperfusion in a rat model\cite{9}. The cardioprotective effects of pitavastatin-NP on IR injury in wild-type mice also appear to be blunted in CCR2-deficient mice (unpublished observations by our laboratory). Overall, these data in small animal models suggest that monocyte-mediated inflammation plays a central role in the mechanism by which pitavastatin-NP exerts cardioprotection against IR injury induced by MI. Although we could not show direct evidence of reduced inflammation in the IR myocardium in the present study due to a lack of antibodies that cross react with porcine monocytes, we showed that pitavastatin-NP reduced oxidative stress, which is associated with inflammation\cite{33}, in the IR-injured myocardium. Inflammatory cells recruited into IR-injured myocardium generate reactive

![Image](A) Representative light (left) and fluorescence (right) images of heart cross-sections 2 hours after intravenous injections of saline or pitavastatin-NP (16 mg/body of pitavastatin). The Evans blue-stained areas stained in the left row indicate the non-ischemic areas, and the pale areas indicate the ischemic areas. The black area in the right row indicates the no-reflow area. Scale bar: 1 cm. (B) The effects of pitavastatin-NP on the no-reflow area. The data are expressed as means ± SEM (n = 5 each) and were compared using an unpaired t-test.

doi:10.1371/journal.pone.0162425.g005
Fig 6. The Effect of Pitavastatin-NP on Cultured Cardiomyocytes Subjected to Hypoxia/Reoxygenation.  
(A) Cultured cardiomyocytes were subjected to hypoxia/reoxygenation (H/R), and cell death was characterized as apoptosis (annexin V FITC-positive/PI-negative) or necrosis (PI-positive), as determined by flow cytometry. The white bars indicate the pitavastatin-NP-treated groups. The data are expressed as means ± SD (N = 6 each). *P < 0.05, **P < 0.01 between the two groups indicated by the bar, as determined by two-way ANOVA followed by Sidak’s multiple comparison test. #P < 0.01 versus the vehicle group with H/R, as determined by two-way ANOVA followed by Sidak’s multiple comparison test.  
(B) Confocal microscopy of neonatal rat ventricular cardiomyocytes subjected to H/R. The cells were co-incubated with vehicle, FITC or FITC-NP, and the nuclei were stained with Hoechst 33342 (blue). Scale bar: 20 μm.  
(C) Quantitation of the FITC signals of 5 randomly selected microscopic fields of view. The data are expressed as means ± SD and were compared using one-way ANOVA followed by Dunnett’s multiple comparison test.

doi:10.1371/journal.pone.0162425.g006
oxygen species and stimulate the release of pro-apoptotic factors in the ischemic myocardium [34], resulting in cardiomyocyte apoptosis after IR [33]. In the present study, we showed that PLGA nanoparticles are incorporated by cultured cardiomyocytes under hypoxia-reoxygenation, and pitavastatin-NP exerts a direct anti-apoptotic effect on cultured cardiomyocytes undergoing hypoxia-reoxygenation. However, further studies are needed to determine the mechanism by which pitavastatin-NP exerts its anti-apoptotic effect on IR injury in vivo.

In summary, treatment with pitavastatin-NP exerts cardioprotective effects on IR injury without apparent adverse side effects in a preclinical conscious porcine model. This nanotechnology-based approach can be developed as a novel therapeutic strategy for the treatment of patients presenting with AMI. Indeed, we have conducted phase I clinical trials (UMIN000014940, UMIN000019189) of intravenous injections of pitavastatin-NP. We are also conducting a phase I/IIa clinical trial (UMIN000008011) of intramuscular injections of pitavastatin-NP in patients with critical limb ischemia. We are now planning to perform a phase IIa clinical trial for patients with AMI.

Supporting Information

S1 Fig. Experimental Protocols. (A) Experimental protocol 1: Protocol for measuring the MI size in mini-pigs. Five minutes prior to reperfusion, the pigs were divided into four groups treated intravenously with the following drugs: 1) saline (10 mL/body), 2) FITC-NP (PLGA containing 10 mg of FITC in saline; 10 mL/body), 3) pitavastatin alone (8 mg in saline; 10 mL/body), or 4) pitavastatin-NP (PLGA containing 4, 8, 16, or 32 mg of pitavastatin in saline; 10 mL/body). Before and during the ischemia-reperfusion procedure, an electrocardiogram at the left precordial lead, arterial blood pressure, heart rate and body temperature were continuously monitored using a telemetry system without administering anesthesia. Blood sampling was performed at baseline (1 hour prior to ischemia) and 24 hours after reperfusion. To measure the MI size, the animals were euthanized 24 hours after reperfusion with an overdose of pentobarbital, and the hearts were excised. The LCx was re-occluded, and the MI size was measured using 1.0% Evans blue and 1.0% triphenyltetrazolium chloride staining. (B) Experimental protocol 2: Western blot protocol for the samples from the mini-pigs. Four pigs treated with FITC-NP (PLGA containing 10 mg of FITC in saline; 10 mL/body) and 5 pigs treated with pitavastatin-NP (PLGA containing 16 mg of pitavastatin in saline; 10 mL/body) were euthanized 2 hours after reperfusion, and tissues were harvested from the non-ischemic and ischemic areas. (C) Experimental protocol 3: Immunohistochemistry and TUNEL staining protocols for the samples from the mini-pigs. Four pigs treated with FITC-NP (PLGA containing 10 mg of FITC in saline; 10 mL/body) and 5 pigs treated with pitavastatin-NP (PLGA containing 16 mg of pitavastatin in saline; 10 mL/body) were euthanized 24 hours after reperfusion, and tissues were harvested from the non-ischemic and ischemic areas. (D) Experimental protocol 4: Protocol for cardiac MRI in mini-pigs. Eight pigs each from the saline- (10 mL/body) and pitavastatin-NP-treated (PLGA containing 16 mg of pitavastatin in saline; 10 mL/body) groups were monitored until 4 weeks after reperfusion, and cardiac MRI was performed to assess cardiac function and left ventricular remodeling.

(TIF)

S2 Fig. Experimental Protocols. (A) Experimental protocol 5: Protocol for the domestic pigs used for the tracing study. Two pigs each were treated with either saline, FITC (0.33 mg/kg in saline; 10 mL/body), or FITC-NP (PLGA containing 0.33 mg/kg FITC in saline; 10 mL/body) 5 minutes before reperfusion, and 2 hours after reperfusion, the pigs were euthanized, and the hearts were excised. The LCx was re-occluded, and 1.0% Evans blue was injected into both coronary arteries. The left ventricles were sectioned into 10-mm-thick cross-sectional myocardial
slices and were photographed by fluorescence stereomicroscopy. (B) Experimental protocol 6: Protocol for domestic pigs used for the pharmacokinetic study. Pitavastatin (16 mg/body) or pitavastatin-NP (16 mg/body) were intravenously injected 5 minutes prior to reperfusion. Serial blood sampling and biopsy of the ischemic and non-ischemic myocardium were performed 5, 15, 30 or 60 minutes after reperfusion to measure the plasma and tissue concentrations of pitavastatin. (C) Experimental protocol 7: Protocol for domestic pigs used to assess the no-reflow areas. Pigs treated with saline (10 mL/body) or pitavastatin-NP (PLGA containing 16 mg of pitavastatin in saline; 10 mL/body) were reperfused for 2 hours, and 4% thioflavin S was injected into the left coronary artery via a 7-Fr catheter. Then, the animals were euthanized, and the heart was excised. The LCx was re-occluded, and 1% Evans blue was injected into both coronary arteries. The left ventricles were sectioned into 10-mm-thick cross-sectional myocardial slices and were photographed with a digital camera.

S3 Fig. Scheme illustrating the method for grouping the experimental animals. (A) Mini-pigs used to measure the MI size. (B) Mini-pigs used for western blot, immunohistochemistry and TUNEL staining. (C) Mini-pigs used for cardiac MRI. (D) Domestic pigs used for the tracing and pharmacokinetic studies. (E) Domestic pigs used to assess the no-reflow areas.

S4 Fig. Effects of Saline, FITC-NP, Pitavastatin and Pitavastatin-NP on MI Size in Mini-Pigs. (A) The effects of saline (n = 7) and FITC-NP (n = 4) on MI size. The data are expressed as means ± SEM and were compared using an unpaired t-test. (B) The area at risk as a percentage of the left ventricle (LV). The data are expressed as means ± SEM (n = 4–7 each) and were compared using an unpaired t-test. (C) The effects of saline (n = 7), pitavastatin (8 mg/body, n = 3) and pitavastatin-NP (8 mg/body of pitavastatin, n = 7) on MI size. The data are expressed as means ± SEM and were compared using one-way ANOVA followed by Tukey’s multiple comparison test. (D) The area at risk as a percentage of the left ventricle (LV). The data are expressed as means ± SEM (n = 3–7 each) and were compared using one-way ANOVA followed by Tukey’s multiple comparison test.

S5 Fig. Flow Cytometric Analysis of Cell Death in Cultured Cardiomyocytes. (A) Gating strategy to identify the apoptotic and necrotic cells in cultured cardiomyocytes. Apoptosis was defined as annexin V FITC-positive/propidium iodide (PI)-negative cells, whereas necrosis was defined as PI-positive cells. (B) Representative dot plots and histograms of cells treated with vehicle, pitavastatin alone (10 μmol/L) or pitavastatin-NP (10 μmol/L) with or without mevalonic acid (100 μmol/L).

Acknowledgments
We thank Eiko Iwata and Satomi Abe for their excellent technical assistance.

Author Contributions
Conceived and designed the experiments: KI TM KN KE.
Performed the experiments: KI KN MT KH.
Analyzed the data: KI TM JK KE.
Wrote the paper: KI TM JK KE.
References

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 2015; 131.e29–322. doi: 10.1161/CIR.0000000000000152 PMID: 25520374

2. Stone GW, Selker HP, Thiele H, Patel MR, Udelsan JE, Ohman EM, et al. Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. Journal of the American College of Cardiology 2016; 67:1674–83. doi: 10.1016/j.jacc.2016.01.069 PMID: 27056772

3. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357:1121–35. PMID: 17855673

4. Ludman A, Venugopal V, Yellon DM, Hausenloy DJ. Statins and cardioprotection—more than just lipid lowering? Pharmacology and Therapeutics 2009; 122:30–43. doi: 10.1016/j.yphar.2009.01.002 PMID: 19318042

5. Ishikita A, Matoba T, Ikeda G, Koga J-I, Mao Y, Nakano K, et al. Nanoparticle-Mediated Delivery of Mitochondrial Division Inhibitor 1 to the Myocardium Protects the Heart From Ischemia-Reperfusion Injury Through Inhibition of Mitochondria Outer Membrane Permeabilization: A New Therapeutic Modality for Acute Myocardial Infarction. Journal of the American Heart Association 2016;5.

6. Nakano Y, Matoba T, Tokutome M, Funamoto D, Katsuki S, Ikeda G, et al. Nanoparticle-Mediated Delivery of Ibesartan Induces Cardioprotection from Myocardial Ischemia-Reperfusion Injury by Antagonizing Monocyte-Mediated Inflammation. Sci Rep 2016; 6:29601. doi: 10.1038/srep29601 PMID: 27403534

7. Nakashiro S, Matoba T, Umez R, Koga J-I, Tokutome M, Katsuki S, et al. Pioglitazone-Incorporated Nanoparticles Prevent Plaque Destabilization and Rupture by Regulating Monocyte/Macrophage Differentiation in ApoE-/- Mice. Arterioscler. Thromb. Biol. 2016; 36:491–500. doi: 10.1161/ATVBAHA.115.307057 PMID: 26821947

8. Ikeda G, Matoba T, Nakano Y, Nagaoka K, I Ishikita A, Nakano K, et al. Nanoparticle-Mediated Targeting of Cyclosporine A Enhances Cardioprotection Against Ischemia-Reperfusion Injury Through Inhibition of Mitochondrial Permeability Transition Pore Opening. Sci Rep 2016; 6:1–13.

9. Nagaoka K, Matoba T, Mao Y, Nakano Y, Ikeda G, Egusa S, et al. A New Therapeutic Modality for Acute Myocardial Infarction: Nanoparticle-Mediated Delivery of Pitavastatin Induces Cardioprotection from Ischemia-Reperfusion Injury via Activation of PI3K/Akt Pathway and Anti-Inflammation in a Rat Model. PLoS ONE 2015; 10:e0132451. doi: 10.1371/journal.pone.0132451 PMID: 26167913

10. Katsuki S, Matoba T, Nakashiro S, Sato K, Koga JI, Nakano K, et al. Nanoparticle-Mediated Delivery of Pitavastatin Inhibits Atherosclerotic Plaque Destabilization/Rupture in Mice by Regulating the Recruitment of Inflammatory Monocytes. Circulation 2014; 129:896–906. doi: 10.1161/CIRCULATIONAHA.113.002870 PMID: 24305567

11. Chen L, Nakano K, Kimura S, Matoba T, Iwata E, Miyagawa M, et al. Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension. Hypertension 2011; 57:343–50. doi: 10.1161/HYPERTENSIONAHA.110.157032 PMID: 21220711

12. Oda S, Nagahama R, Nakano K, Matoba T, Kubo M, Sunagawa K, et al. Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia. J. Vasc. Surg. 2010; 52:412–20. doi: 10.1016/j.jvs.2010.03.020 PMID: 20373471

13. Kubo M, Egashira K, Inoue T, Koga J-I, Oda S, Chen L, et al. Therapeutic neovascularization by nanotechnology-mediated cell-selective delivery of pitavastatin into the vascular endothelium. Arterioscler. Thromb. Vasc. Biol. 2009; 29:796–801. doi: 10.1161/ATVBAHA.108.182594 PMID: 19325146

14. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Advanced Drug Delivery Reviews 2011; 63:170–83. doi: 10.1016/j.addr.2010.10.008 PMID: 20965219

15. Suzuki Y, Yeung AC, Ikeno F. The Representative Porcine Model for Human Cardiovascular Disease. Journal of Biomedicine and Biotechnology 2011; 2011:1–10.

16. Heusch G, Skyshchaly A, Schulz R. The in-situ pig heart with regional ischemia/reperfusion—ready for translation. J. Mol. Cell. Cardiol. 2011; 50:951–63. doi: 10.1016/j.yjmcc.2011.02.016 PMID: 21382377

17. Bardají Á, Cinca J, Werner F, Schoenenberger A. Effects of anaesthesia on acute ischaemic arrhythmias and epicardial electrogamers in the pig heart in situ. Cardiovascular Research 1990; 24:227–31. PMID: 16933111

18. Kehl F, Krolikowski JG, Mrčovic B, Pagel PS, Wartlter DC, Kersten J. Is isoflurane-induced preconditioning dose related? Anesthesiology 2002; 96:765–70. PMID: 11873044
19. Van Allen NR, Krafft PR, Leitzke AS, Applegate RL, Tang J, Zhang JH. The role of Volatile Anesthetics in Cardioprotection: a systematic review. Med Gas Res 2012; 2:22. doi: 10.1186/2045-9912-2-22 PMID: 22929111

20. Malliaras K, Smith RR, Kanazawa H, Yee K, Seinfeld J, Tseliou E, et al. Validation of Contrast-Enhanced Magnetic Resonance Imaging to Monitor Regenerative Efficacy After Cell Therapy in a Porcine Model of Convalescent Myocardial Infarction. Circulation 2013; 128:2764–75. doi: 10.1161/CIRCULATIONAHA.113.002863 PMID: 24061088

21. Bune LT, Larsen JR, Thaning P, Bune NET, Rasmussen P, Rosenmeier JB. Adenosine diphosphate reduces infarct size and improves porcine heart function after myocardial infarct. Physiol Rep 2013; 1:e00003. doi: 10.1002/PHY2.3 PMID: 24303097

22. Kapur NK, Paruchuri V, Urbano-Morales JA, Mackey EE, Daly GH, Qiao X, et al. Mechanically unloading the left ventricle before coronary reperfusion reduces left ventricular wall stress and myocardial infarct size. Circulation 2013; 128:328–36. doi: 10.1161/CIRCULATIONAHA.112.000029 PMID: 23766531

23. Suzuki Y, Lyons JK, Yeung AC, Ikono F. In vivo porcine model of reperfused myocardial infarction: in situ double staining to measure precise infarct area/area at risk. Catheter Cardiovasc Interv 2008; 71:100–7. PMID: 17985383

24. Liu Y, Zeng B-H, Shang H-T, Cen Y-Y, Wei H. Bama miniature pigs (Sus scrofa domestica) as a model for drug evaluation for humans: comparison of in vitro metabolism and in vivo pharmacokinetics of lovastatin. Comp. Med. 2008; 58:580–7. PMID: 19149415

25. Kimura S, Egashira K, Nakano K, Iwata E, Miyagawa M, Tsujimoto H, et al. Local delivery of imatinib mesylate (ST1571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation. Circulation 2008; 118:S65–70. doi: 10.1161/CIRCULATIONAHA.107.740613 PMID: 18824771

26. Lønborg J, Kelbaek H, Vejlstrup N, Jørgensen E, Helqvist S, Saunamäki K, et al. Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. Circulation: Cardiovascular Interventions 2010; 3:34–41.

27. Bodi V, Ruiz-Nodar JM, Feliu E, Minana G, Nunez J, Husser O, et al. Effect of ischemic postconditioning on microvascular obstruction in reperfused myocardial infarction. Results of a randomized study in patients and of an experimental model in swine. International Journal of Cardiology 2014; 175:138–46. doi: 10.1016/j.ijcard.2014.05.003 PMID: 24856802

28. Fujino T, Ide T, Yoshida M, Onitsuka K, Tanaka A, Hata Y, et al. Recombinant mitochondriod transcription factor A protein inhibits nuclear factor of activated T cells signaling and attenuates pathological hypertrophy of cardiac myocytes. Mitochondrion 2012; 12:449–58. doi: 10.1016/j.mito.2012.06.002 PMID: 22709542

29. Qi H, Cao Y, Huang W, Liu Y, Wang Y, Li L, et al. Crucial role of calcium-sensing receptor activation in cardiac injury of diabetic rats. PLoS ONE 2013; 8:e65147. doi: 10.1371/journal.pone.0065147 PMID: 23717692

30. Fletcher PJ, Pfeffer JM, Pfeffer MA, Braunwald E. Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction. Effects on systolic function. Circ. Res. 1981; 49:618–26. PMID: 7261261

31. Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E. Progressive ventricular remodeling in rat with myocardial infarction. Am. J. Physiol. 1991; 260:H1406–14. PMID: 2035662

32. Saxena V, Sadoqi M, Shao J. Polymeric nanoparticulate delivery system for Indocyanine green: Biodistribution in healthy mice. International Journal of Pharmaceutics 2006; 308:200–4. PMID: 16986861

33. Zweier JL, Talukder MAH. The role of oxidants and free radicals in reperfusion injury. Cardiovascular Research 2006; 70:181–90. PMID: 16580855

34. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovascular Research 2004; 61:481–97. PMID: 14962479